| Objective To study the impact of Yuxuebi tablets plus anti-osteoporosis drugs on the knee joint function scores of knee osteoarthritis patients. Methods 90 knee osteoarthritis patients treated from March 2019 to February 2020 in our hospital were selected and divided into study group (45 cases) and control group (45 cases) according to the random double-blind method. The study group took Yuxuebi tablets and anti-osteoporosis drugs; the control group just took anti-osteoporosis drugs. Total effective rate, IL-8 (interleukin-8), CRP (C-reactive protein), TNF-α (tumor necrosis factor-α) as well as VAS (visual analogue scale), Lysholm scores, QOL (quality of life) scores were measured. Results Total effective rate in the study group (91.11%) was significantly higher than that in the control group (80.00%) (P<0.05); adverse event rate in the study group (6.67%) and control group (8.89%) showed no statistically significant difference (P>0.05); before medication, the serum inflammatory factors between groups showed no statistically significant difference (P>0.05); after medication, IL-8, CRP and TNF-α levels in the study group were lower than those in the control group (P<0.05); before medication, clinical assessment scores between groups showed no statistically significant difference (P>0.05); after medication, VAS and Lysholm scores in the study group were better than those in the control group (P<0.05); before medication, QOL scores between groups showed no statistically significant difference (P>0.05); after medication, the scores of appetite, spirit, sleep and daily life in the study group were higher than those in the control group (P<0.05). Conclusion Yuxuebi tablets combined with anti-osteoporosis drugs produce no effects on adverse reactions, improve the knee joint function, relieve the pain and inflammation response, and increase the quality of life. |